confusing!

A few days ago, an announcement on the progress of outbound investment by Tibet Pharmaceuticals put itself and its partner Si Microbiology on the cusp of public opinion

Tibet Pharmaceuticals announced that due to the long listing cycle of mRNA vaccine products, and it is expected that large clinical and industrialization costs and risks will continue to be incurred in the future, the company's initial investment of 70 million yuan in Simicrobiology will become an equity investment

Tibet Pharmaceuticals has invested in three products including the new microbial mRNA new crown vaccine in 2020, and cooperated with Russia's LIMITED LIABILITY COMPANY "HUMAN VACCINE" on Sputnik-Vaccine (new crown pneumonia adenovirus vaccine).

Although the capital enthusiasm for blessing in Tibet's pharmaceutical industry has long since faded, the change from a vaccine partner to a shareholder and the abandonment of the global exclusive rights to develop, produce, use and commercialize mRNA vaccines has still caused considerable shock in the industry.

Earlier this year, Chen Dabin, chairman of Tibet Pharmaceuticals, said in an interview with the media that the Russian vaccine project and the company’s investment in Sri Lanka's microbial new crown mRNA vaccine represent the company’s short-term and medium- and long-term plans, and the investment in the new crown vaccine also means The company will strategically transform from a pharmaceutical company to a "pharmaceutical + vaccine" direction

Only 8 months have passed since the new crown mRNA vaccine of Sri Lanka was approved for clinical use.

01 Say goodbye to the concept of mRNA vaccines?

The partner of Tibet Pharmaceuticals is Simicrobiology, a star company that is currently the hottest mRNA vaccine research and development company in China

Tibet Pharmaceuticals reached an agreement with Sri Lanka Microbiology in June 2020 to acquire the global exclusive development, registration, production, use and commercialization rights of Sri Microbiology's new crown vaccine, tuberculosis vaccine and influenza vaccine for a total of 351 million yuan

One of the most eye-catching is the mRNA vaccine of the microbe

Now one year later, Pfizer/BioNTech's new mRNA vaccine has been formally approved by the FDA recently

According to the announcement, Tibet Pharmaceuticals converted the 70 million yuan paid to Sri Microbiology into an equity investment in Sri Microbiology, holding a 3.

The announcement shows that Tibet Pharmaceuticals will no longer enjoy the exclusive global development, production, use and commercialization rights of mRNA vaccines agreed under the original "Strategic Cooperation Agreement

Regarding the changes in the cooperation between Tibet Pharmaceuticals and Sri Lanka Microbiology, Tibet Pharmaceuticals stated that the reason is that on the one hand, it is to achieve more effective long-term strategic cooperation, and on the other hand, it is to reduce the company's investment risk

On the one hand, in the past year, Tibet Pharmaceuticals has also attached great importance to the cooperation with Sri Lanka Microbiology, and it has indeed invested real money

On the other hand, after changing the direction of cooperation, is it cost-effective for Tibet Pharmaceuticals to trade its 3.

Some investors believe that Sri Lanka has 50 shareholders, and on June 3, it announced a new round of financing of nearly 200 million US dollars

According to the announcement, the compensation for the early human, material and financial resources of Tibet Pharmaceutical Industry by Sri Microbiology is 3 million yuan
.
In addition, under the terms of the repurchase agreement in the "Cooperation Framework Agreement", if Microbiology did not realize the IPO within the agreed time, Tibet Pharmaceuticals requested that Microbiology repurchase all the shares of Microbiology held by Tibet Pharmaceuticals for an investment principal of 7000.
Ten thousand yuan and an annualized 10% interest
.

Intriguingly, in May of this year, Tibet Pharmaceutical once stated on the investor interaction platform that the company has no plans to participate in the company's microbiology
.
In the past less than 4 months, why did Tibet Pharmaceuticals change its mind?

02 Is "Tuyere" really fragrant?

At that time, Chen Dabin once stated that Tibet Pharmaceuticals' investment in Sri Lanka's microorganisms was based on the importance of the mRNA technology platform
.

Established in 2016, Sri Microbiology is the earliest company in China to carry out the research and development and production of mRNA drugs
.
Judging from the disclosed R&D pipeline, it involves two major therapeutic areas of infectious diseases and tumor immunology, including a variety of products based on mRNA technology such as the new crown mRNA vaccine, HPV vaccine, and intratumoral injection of mRNA drugs
.

The global pandemic of the new crown epidemic has given the rise of mRNA technology a "window"
.
Whether it is the new crown vaccine BNT162b2 developed in cooperation with BioNTech, it will reach 11.
3 billion U.
S.
dollars in sales in the first half of 2021, and the annual sales revenue is expected to reach 33.
5 billion U.
S.
dollars.
It is expected to return to the world's largest pharmaceutical company Pfizer; Moderna and BioNTech, which have exceeded hundreds of billions of dollars and more than a large number of old MNCs, are now inseparable from the discussion around them-mRNA
.

As a member of the "Tuyere", there are many competitors in Microbiology
.
At present, no mRNA vaccine has been approved for marketing in the domestic market.
Among the eight domestic companies engaged in mRNA vaccine research and development, Fosun Pharma has made the fastest progress
.

Another leading position is ARCoV, which is jointly developed by Abbio, Watson and the Academy of Military Sciences.
It passed the clinical trial approval of the National Medical Products Administration in June last year.
It is the first mRNA approved for clinical trials in China.
Vaccine
.
At present, the vaccine has completed phase I and phase II clinical studies, and has started clinical phase III trials
.

Compared with these two vaccines, Sri Lanka's progress in the development of new coronavirus mRNA vaccines in China is relatively lagging
.

In January 2020, Sri Microbiology announced the launch of the new crown mRNA vaccine research and development project
.
One year after the initiation of the project, in January 2021, Sri Lanka Microbiology announced that it had received the "Drug Clinical Trial Approval" for the mRNA novel coronavirus pneumonia vaccine approved and issued by the State Food and Drug Administration, although this is the second independent research and development approved for clinical trials in China The mRNA new crown vaccine, but it has been behind Watson's ARCoV research and development progress by half a year
.

In March of this year, S.
Microbiology announced that the mRNA vaccine is about to enter the first clinical phase
.
However, for a long time since then, there has been no noticeable progress in the new crown mRNA vaccine of Sri Lanka
.
"In the initial stage of the new crown mRNA similar project, Sri Lanka Microbes did walk in the first echelon, but later fell behind.
There are many reasons
.
" Chen Dabin once responded to the question about whether the research and development progress of Sri Lanka Microbes is behind
.

Until August of this year, Zhang Jiguo, Chief Commercial Officer and Chief Operating Officer of Sri Microbiology, revealed the company’s mRNA vaccine research and development at the 2021 National Pharmaceutical Industry Information Conference: “The first phase of clinical research has ended.
The vaccine is also applying for clinical trials
.
"

Competing for the first approval has become the tacit goal of all major mRNA vaccine companies.
For Sri Microbiology, which is still in the completion of phase I clinical phase, whether it is Fosun Pharma, which has “applied for conditional approval for listing”, or Watson Bio, which has entered the Phase III clinical trial, does not have the first-mover advantage
.
Some investors said to the E-pharmaceutical manager that Tibet Pharmaceutical’s abandonment of the commercialization rights of the mRNA new crown vaccine may be related to the current clinical progress of Sri Lanka Microbiology and the obvious decline in the research and development progress
.